Advertisement

 

 

Loss of TDP43 inhibits progression of triple-negative breast cancer in coordination with SRSF3.

Loss of TDP43 inhibits progression of triple-negative breast cancer in coordination with SRSF3.
Author Information (click to view)

Ke H, Zhao L, Zhang H, Feng X, Xu H, Hao J, Wang S, Yang Q, Zou L, Su X, Wang L, Wu C, Wang Y, Nie J, Jiao B,


Ke H, Zhao L, Zhang H, Feng X, Xu H, Hao J, Wang S, Yang Q, Zou L, Su X, Wang L, Wu C, Wang Y, Nie J, Jiao B, (click to view)

Ke H, Zhao L, Zhang H, Feng X, Xu H, Hao J, Wang S, Yang Q, Zou L, Su X, Wang L, Wu C, Wang Y, Nie J, Jiao B,

Advertisement

Proceedings of the National Academy of Sciences of the United States of America 2018 03 26115(15) E3426-E3435 doi 10.1073/pnas.1714573115

Abstract

Aberrant alternative splicing has been highlighted as a potential hallmark of cancer. Here, we identify TDP43 (TAR DNA-binding protein 43) as an important splicing regulator responsible for the unique splicing profile in triple-negative breast cancer (TNBC). Clinical data demonstrate that TDP43 is highly expressed in TNBC with poor prognosis. Knockdown of TDP43 inhibits tumor progression, including proliferation and metastasis, and overexpression of TDP43 promotes proliferation and malignancy of mammary epithelial cells. Deep sequencing analysis and functional experiments indicate that TDP43 alters most splicing events with splicing factor SRSF3 (serine/arginine-rich splicing factor 3), in the regulation of TNBC progression. The TDP43/SRSF3 complex controls specific splicing events, including downstream genes and The effect of reduced metastasis and proliferation upon the knockdown of TDP43 or SRSF3 is mediated by the splicing regulation of and exon 12, respectively. The TDP43/SRSF3 complex and downstream PAR3 isoform are potential therapeutic targets for TNBC.

Submit a Comment

Your email address will not be published. Required fields are marked *

three × 5 =

[ HIDE/SHOW ]